SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma Advanced Research Company informs about press release

14 May 2021 Evaluate

Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, Sun Pharma Advanced Research Company has informed that it has enclosed the Press Release on 14th May 2021 titled ‘SPARC Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of PDP-716 for the Treatment of Open Angle Glaucoma or Ocular Hypertension’ which is self-explanatory.

The above information is a part of company’s filings submitted to BSE.

Sun Pharma Adv. Res Share Price

147.90 -4.25 (-2.79%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internation. 435.70
Indegene 486.80
CMS Info Systems 318.00
JITF Infralogistics 338.00
Sagility 42.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×